Logo

CASI Pharmaceuticals, Inc.

CASI

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipel… read more

Healthcare

Biotechnology

29 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$1.38

Price

+3.76%

$0.05

Market Cap

$21.380m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-262.4%

EBITDA Margin

-320.4%

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$31.564m

+10.6%

1y CAGR

-8.9%

3y CAGR

+4.1%

5y CAGR
Earnings

-$46.890m

-19.4%

1y CAGR

-11.2%

3y CAGR

-9.5%

5y CAGR
EPS

-$3.04

-18.7%

1y CAGR

-5.1%

3y CAGR

-4.8%

5y CAGR
Book Value

-$20.310m

$31.202m

Assets

$51.512m

Liabilities

$18.734m

Debt
Debt to Assets

60.0%

-0.5x

Debt to EBITDA
Free Cash Flow

$0.00

+100.0%

1y CAGR

+28.1%

3y CAGR

+30.3%

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases